

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07K 14/62, A61K 38/28</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/42749</b> <b>(43) International Publication Date:</b> 1 October 1998 (01.10.98)
<b>(21) International Application Number:</b> PCT/DK98/00109 <b>(22) International Filing Date:</b> 20 March 1998 (20.03.98) <b>(30) Priority Data:</b> 0317/97                      20 March 1997 (20.03.97)                      DK <b>(71) Applicant (for all designated States except US):</b> NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> HAVELUND, Svend [DK/DK]; Kurvej 24, DK-2880 Bagsvaerd (DK). <b>(74) Common Representative:</b> NOVO NORDISK A/S; Novo Allé, DK-2880 Bagsvaerd (DK).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> ZINC FREE INSULIN CRYSTALS FOR USE IN PULMONARY COMPOSITIONS		
<b>(57) Abstract</b>  Zinc free insulin crystals having a diameter below 10 $\mu$ m suitable for pulmonary administration are disclosed. The crystals have a reduced tendency to associate into aggregates in the dry powder.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## ZINC FREE INSULIN CRYSTALS FOR USE IN PULMONARY COMPOSITIONS

**Field of the invention**

The present invention relates to zinc free insulin crystals having a diameter below 10  $\mu\text{m}$  and to therapeutic powder formulations suitable for pulmonary administration comprising such insulin crystals.

**5 Background of the invention**

Diabetes is a general term for disorders in man having excessive urine excretion as in diabetes mellitus and diabetes insipidus. Diabetes mellitus is a metabolic disorder in which the ability to utilize glucose is more or less completely lost. About 2 % of all people suffer from diabetes.

- 10 Since the introduction of insulin in the 1920's, continuous strides have been made to improve the treatment of diabetes mellitus. To help avoid extreme glycaemia levels, diabetic patients often practice multiple injection therapy, whereby insulin is administered with each meal.

- 15 Insulin is usually administrated by s.c. or i.m. injections. However, due to the adherent discomfort of injections alternative ways of administration such as nasal and pulmonary has been extensively investigated. For a review on alternative routes of administration of insulin, see Danielsen et al. New routes and means of insulin delivery, in: Childhood and Adolescent Diabetes (Ed. Kelnar), Chapman & Hall Medical, London 1994, pp. 571-584.

- 20 In order to circumvent injections, administration of insulin via the pulmonary route could be an alternative way to provide absorption profiles which mimic the endogenous insulin without the need to inject the insulin.

**Description of the background art**

- 25 Administration of insulin via the pulmonary route can be accomplished by either an aqueous solution or a powder preparation. A description of the details can be found in several references, one of the latest being by Niven, Crit. Rev. Ther. Drug Carrier Sys, 12(2&3):151-231 (1995). One aspect covered in said review is the stability issue of protein formulations, aqueous solutions being less stable than powder formulation. So far, all powder formulations have been described as mainly amorphous.

A review of the permeation enhancers useful for the promotion of trans-mucosal absorption is found in Sayani et al., Crit. Rev. Ther. Drug Carrier Sys, 13(1&2): 85-184 (1996).

Patton et al., Inhale Therapeutic Systems, PCT WO 95/24183, claim a method for aerosolising a dose of insulin comprising providing the insulin as a dry powder dispersing  
5 an amount of the dry powder in a gas stream to form an aerosol capturing the aerosol in a chamber for subsequent inhalation.

It has been found that when insulin is combined with an appropriate absorption enhancer and is introduced into the lower respiratory tract in the form of a powder of appropriate particle size, it readily enters the systemic circulation by absorption through the layer of  
10 epithelial cells in the lower respiratory tract as described in US patent No. 5,506,203. The manufacturing process described in said patent, comprising dissolution of insulin at acid pH followed by a pH adjustment to pH 7.4 and addition of sodium taurocholate before drying the solution by vacuum concentration, open drying, spray drying, or freeze drying, results in a powder composed of human insulin and absorption enhancer. The powder is  
15 characterized as mainly amorphous determined under a polarized light microscope. The desired particle size distribution is achieved by micronizing in a suitable mill, such as a jet mill, and the components may be mixed before or after micronizing. The biological effect of the powder obtained according to the methods described in this patent is only seen in the presence of a substantial amount of enhancer.

20 Platz et al., Inhale Therapeutic Systems, PCT WO 96/32149, describes spray drying of zinc insulin from a solution containing mannitol and a citrate buffer, pH 6.7. The inlet temperature is 120 to 122°C, the outlet temperature 80-81°C. The mass median aerodynamic diameter, MMAd, of the obtained insulin particles was determined to 1.3 to 1.5 µm.

In his thesis, "Insulin Crystals", Munksgaard Publisher 1958, p. 54-55, Schlichtkrull  
25 describes crystallisation of zinc free, recrystallised porcine insulin from a solution comprising 0.01 M sodium acetate and 0.7% ~ 0.12 M sodium chloride and 0.1% methylparahydroxybenzoate and using a pH of 7.0. The crystals obtained were 10-50 µm rhombic dodecahedral crystals showing no birefringence.

Jackson, US Patent No. 3,719,655 describes a method of purification of crude porcine and  
30 bovine insulin by crystallisation. Zinc free crystals of insulin are obtained by crystallisation at pH 8.2 (range 7.2-10) in the presence of 0.5 M (range 0.2 M - 1 M) of a sodium,

potassium, lithium or ammonium salt. Crystallisation is achieved by addition of 1 N alkali metal hydroxide or 1 N ammonia to a solution of crude insulin in 0.5 N acetic acid to a pH of 8.2 is obtained. Alternatively, crystallisation is achieved in an aqueous solution of impure insulin at pH 8.2 by addition of solid sodium chloride to a concentration of sodium ions of 0.45 M. The crystals appear in the octadecahedral or dodecahedral forms, *i.e.* crystals belonging to the cubic crystal system.

Baker et al., Lilly, EP 0 709 395 A2 (filed October 31, 1994) describe a zinc free crystallisation process for Lys<sup>B28</sup>-Pro<sup>B29</sup> human insulin characterised by adjustment of the pH of a strongly buffered acid solution containing metal cations or ammonium ions and a preservative with metal hydroxide or ammonia to a value between 8.5 and 9.5.

The known methods for the manufacture of insulin particles of the desired size for pulmonary administration are cumbersome, generates problems with insulin dust and the investments in equipment are large. Furthermore, insulin is exposed to conditions where some denaturation is likely to take place. Thus WO 96/32149 disclose spray drying in a temperature range of 50°C to 100°C, followed by milling of the particles to achieve to desired particle size.

Furthermore, the known powder formulations for pulmonary administration which have been described as mainly amorphous have a tendency to associate into aggregates in the dry powder.

## 20 Description of the invention

### Definitions

The expression "enhancer" as used herein refers to a substance enhancing the absorption of insulin, insulin analogue or insulin derivative through the layer of epithelial cells lining the alveoli of the lung into the adjacent pulmonary vasculature, *i.e.* the amount of insulin absorbed into the systemic system is higher than the amount absorbed in the absence of enhancer.

In the present context the expression "powder" refers to a collection of essentially dry particles, *i.e.* the moisture content being below about 10 % by weight, preferably below 6 % by weight, and most preferably below 4 % by weight.

The diameter of the crystals is defined as the Martin's diameter. It is measured as the length of the line, parallel to the ocular scale, that divides the randomly oriented crystals into two equal projected areas

#### Brief description of the invention

- 5 It is an object of the present invention to provide an insulin powder suitable for pulmonary delivery which has a reduced tendency to associate into aggregates in the dry powder compared to the pulmonary insulin particles described in the prior art.

According to the present invention this object has been accomplished by providing zinc free insulin crystals having a diameter below 10  $\mu\text{m}$ .

- 10 The crystals of the present invention furthermore exhibit a better stability profile than powders of essentially the same composition prepared by spray drying, freeze-drying, vacuum drying and open drying. This is probably due to the amorphous state of powders prepared by the other methods described. By this means it is possible to store the powder formulations based on the crystals of the present invention at room temperature in  
15 contrary to human insulin preparations for injections and some amorphous insulin powders without stabilizing agent which have to be stored between 2°C to 8°C.

Furthermore, therapeutical powder formulations comprising the insulin crystals of the invention elucidates better flowing properties than corresponding amorphous powder formulations.

#### 20 Preferred embodiments

The zinc free insulin crystals of the invention are advantageously provided in a crystal structure belonging to the cubic crystal system, preferably in the octadecahedral or dodecahedral crystal forms, since these crystal forms result in readily soluble product having excellent flowing properties.

- 25 The diameter of the insulin crystals is advantageously kept in the range of 0.2 to 5  $\mu\text{m}$ , preferably in the range of 0.2 to 2  $\mu\text{m}$ , more preferably in the range of 0.5 and 1  $\mu\text{m}$ , to ensure high bioavailability and suitable profile of action, see PCT application No. WO 95/24183 and PCT application No. WO 96/32149.

In a preferred embodiment the insulin used is selected from the group consisting of human

insulin, bovine insulin or porcine insulin, preferably human insulin.

In another preferred embodiment the insulin used is selected from the group consisting of rapid-acting insulins, preferably des(B30) human insulin, Asp<sup>B28</sup> human insulin or Lys<sup>B28</sup>Pro<sup>B29</sup> human insulin.

- 5 In another preferred embodiment the insulin used is an insulin derivative, preferably selected from the group consisting of B29-N<sup>ε</sup>-myristoyl-des(B30) human insulin, B29-N<sup>ε</sup>-palmitoyl-des(B30) human insulin, B29-N<sup>ε</sup>-myristoyl human insulin, B29-N<sup>ε</sup>-palmitoyl human insulin, B28-N<sup>ε</sup>-myristoyl Lys<sup>B28</sup> Pro<sup>B29</sup> human insulin, B28-N<sup>ε</sup>-palmitoyl Lys<sup>B28</sup> Pro<sup>B29</sup> human insulin, B30-N<sup>ε</sup>-myristoyl-Thr<sup>B29</sup>Lys<sup>B30</sup> human insulin, B30-N<sup>ε</sup>-palmitoyl-Thr<sup>B29</sup>Lys<sup>B30</sup> human insulin, B29-N<sup>ε</sup>-(N-palmitoyl-γ-glutamyl)-des(B30) human insulin, B29-N<sup>ε</sup>-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin, B29-N<sup>ε</sup>-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N<sup>ε</sup>-(ω-carboxyheptadecanoyl) human insulin, more preferably Lys<sup>B29</sup>(N-ε acylated) des(B30) human insulin.
- 10

- The insulin derivatives has a protracted onset of action and may thus compensate the very rapid increase in plasma insulin normally associated with pulmonary delivery. By carefully selecting the type of insulin, the present invention enables adjustment of the timing and to obtain the desired biological response within a defined time span.
- 15

- In order to avoid irritation of the lungs and to eliminate immunological reactions, the employed insulin is preferably insulin which has been purified by chromatography, such as MC insulin (Novo), Single Peak insulin (E. Lilly) and RI insulin (Nordisk).
- 20

In a preferred embodiment the zinc free insulin crystals according to the invention further comprise a stabilizing amount of a phenolic compound, preferably m-cresol or phenol, or a mixture of these compounds.

- The present invention is furthermore concerned with a therapeutic powder formulation suitable for pulmonary administration comprising the zinc free crystals described above.
- 25

In a preferred embodiment this therapeutic powder formulation further comprises an enhancer which enhances the absorption of insulin in the lower respiratory tract.

The enhancer is advantageously a surfactant, preferably selected from the group consisting of salts of fatty acids, bile salts or phospholipids, more preferably a bile salt.

- Preferred fatty acids salts are salts of C<sub>10-14</sub> fatty acids, such as sodium caprate, sodium laurate and sodium myristate.
- 30

Lysophosphatidylcholine is a preferred phospholipid.

Preferred bile salts are salts of ursodeoxycholate, taurocholate, glycocholate and taurodihydrofusidate. Still more preferred are powder formulations according to the invention wherein the enhancer is a salt of taurocholate, preferably sodium taurocholate.

- 5 The molar ratio of insulin to enhancer in the powder formulation of the present invention is preferably 9:1 to 1:9, more preferably between 5:1 to 1:5, and still more preferably between 3:1 to 1:3.

The powder formulations of the present invention may optionally be combined with a carrier or excipient generally accepted as suitable for pulmonary administration. The  
10 purpose of adding a carrier or excipient may be as a bulking agent, stabilizing agent or an agent improving the flowing properties.

Suitable carrier agents include 1) carbohydrates, e.g. monosaccharides such as fructose, galactose, glucose, sorbose, and the like; 2) disaccharides, such as lactose, trehalose and the like; 3) polysaccharides, such as raffinose, maltodextrins, dextrans, and the like; 4)  
15 alditols, such as mannitol, xylitol, and the like; 5) inorganic salts, such as sodium chloride, and the like; 6) organic salts, such as sodium citrate, sodium ascorbate, and the like. A preferred group of carriers includes trehalose, raffinose, mannitol, sorbitol, xylitol, inositol, sucrose, sodium chloride and sodium citrate.

The crystals of the present invention are advantageously produced according to the  
20 following procedure:

- a) providing a solution of insulin having a pH between 7.0 and 9.5;
  - b) mixing said solution with a solution of a salt of an alkali metal or an ammonium salt;  
and
  - c) recovering the formed crystals.
- 25 The salt of an alkali metal or ammonium is preferably selected from the group consisting of the hydrochloride or acetate of sodium, potassium, lithium or ammonia, or mixtures thereof, more preferably sodium acetate.

In order to suppress the solubility of the crystals formed, the solution of insulin and/or the solution of a salt of an alkali metal or an ammonium salt preferably comprises a water  
30 miscible organic solvent in an amount which corresponds to 5 to 25 % (v/v) in the solution obtained after mixing.



The water miscible organic solvent is preferably selected from the group consisting of ethanol, methanol, acetone and 2-propanol, more preferably ethanol.

- 5 A very uniform distribution of crystal sizes and crystals of the same crystallographic form are obtained when the two solutions are mixed within a period of less than 2 hours, preferably less than 1 hour, more preferably less than 15 minutes, still more preferably less than 5 minutes.

- 10 The crystallisation process by which uniformly sized, small, zinc free crystals is obtained directly, without the use of milling, micronizing, sieving and other dust generating steps, is much to be preferred from the present state of the art in the manufacture of insulin powders for inhalation.

The concentration of insulin after mixing is preferably between 0.5% and 10%, more preferably between 0.5% and 5%, still more preferably between 0.5% and 2%.

The concentration of salt after mixing is preferably between 0.2 M and 2 M, more preferably about 1 M.

- 15 The method according to the present invention may further comprise a washing step, in which the crystals obtained are washed with a solution comprising auxiliary substances to be included in the final dry powder, preferably an enhancer and/or a carbohydrate, and optionally comprising 5-25% of an alcohol, preferably ethanol, 5-50 mM of a preservative preferably phenol, and 0.1-2 M of a salt such as sodium acetate.
- 20 This invention is further illustrated by the following examples which, however, are not to be construed as limiting.

#### EXAMPLE 1

Crystallisation in 1 M sodium acetate.

- 25 2 g of highly purified human insulin is dissolved in 100 ml 10 mM tris buffer, pH 8.0 in 20% (v/v) of ethanol in water. To this solution is added 100 ml 2 M sodium acetate under stirring. A precipitate forms immediately. After 2 days at room temperature microscopy shows small crystals having a diameter between 0.5 and 1  $\mu$ m. The crystals are collected by centrifugation at -10°C, washed once with 20 ml ice cold 10% ethanol (v/v) in water, isolated by centrifugation and dried by lyophilization. The obtained crystals are shown in
- 30 Fig. 1.

## EXAMPLE 2

Crystallisation in the presence of taurocholic acid sodium salt.

10 mg of human insulin and 5 mg of taurocholic acid sodium salt are dissolved in 500  $\mu$ l  
10 mM tris buffer, pH 8.0 in 20 % (v/v) of ethanol in water. To this solution is added 500  $\mu$ l  
5 2 M sodium acetate. Microscopy after 1 hour and after 24 hours shows identically  
appearance of the crystals, *i.e.* uniformly sized crystals having diameters between 0.5 and  
1  $\mu$ m. The crystals were washed three times with 100  $\mu$ l 10 % (v/v) ethanol in water at -  
10°C and dried *in vacuo*. HPLC of the crystals showed that the washings had removed the  
taurocholic acid sodium salt from the insulin crystals.

10

## EXAMPLE 3

Crystallisation in the presence of Tween 80, bis(2-ethylhexyl) sulfosuccinate sodium salt,  
chitosan, L- $\alpha$ -lysophosphatidylcholine myristoyl and polyoxyethylene sorbitan monolau-  
rate.

15

Crystallisation was performed as described in Example 2 except that taurocholic acid  
sodium salt was replaced by 0.6% (w/v) Tween 80, 0.56% (w/v) bis(2-ethylhexyl)  
sulfosuccinate sodium salt, 0.32% (w/v) chitosan, 0.52% (w/v) L- $\alpha$ -lysophosphatidylcholine  
myristoyl, and 1% (w/v) polyoxyethylene sorbitan monolaurate, respectively. All five  
20 examples resulted in uniformly sized crystals having diameters between 0.5 and 1  $\mu$ m.

## EXAMPLE 4

Crystallisation in 10% (v/v) ethanol.

Crystallisation was performed in 10% (v/v) ethanol as described in Example 1, using 4  
25 combinations of pH and concentration of sodium acetate:

4.1 : pH 7.5 and 1 M sodium acetate

4.2 : pH 7.5 and 1.5 M sodium acetate

4.3 : pH 9.0 and 1 M sodium acetate

4.4 : pH 9.0 and 1.5 M sodium acetate

5 All 4 combinations yielded uniformly sized crystals having diameters between 0.5 and 1  $\mu\text{m}$ .

#### EXAMPLE 5

10 Crystallisation in 15% (v/v) ethanol.

Crystallisation was performed in 15% (v/v) ethanol, using 6 combinations of pH and concentration of sodium acetate:

- 15 5.1 : pH 7.5 and 1 M sodium acetate  
5.2 : pH 7.5 and 1.5 M sodium acetate  
5.3 : pH 7.5 and 2 M sodium acetate  
5.4 : pH 9.0 and 1 M sodium acetate  
5.5 : pH 9.0 and 1.5 M sodium acetate  
5.6 : pH 9.0 and 2 M sodium acetate

20 All 6 combinations yielded uniformly sized crystals having diameters between 0.5 and 1  $\mu\text{m}$ .

#### EXAMPLE 6

25 Crystallisation in 20% (v/v) ethanol.

Crystallisation was performed in 20% (v/v) ethanol using 4 combinations of pH and concentration of sodium acetate:

- 6.1 : pH 7.5 and 1 M sodium acetate
- 6.2 : pH 7.5 and 1.5 M sodium acetate
- 6.3 : pH 7.5 and 2 M sodium acetate
- 5 6.4 : pH 9.0 and 1 M sodium acetate

All 4 combinations yielded uniformly sized crystals having diameters between 0.5 and 1  $\mu\text{m}$ .

#### 10 EXAMPLE 7

Crystallisation at pH 7.5, 8.0, 8.5 and 9.0 in 20% ethanol (v/v) using slow addition of sodium acetate.

- Crystallisation was performed using solutions as described in Example 1, except that the 2 M sodium acetate was dissolved in 20% (v/v) ethanol in water. The pH of the insulin solutions were adjusted to 7.5, 8.0, 8.5 and 9.0, respectively. The sodium acetate solution was added in 12 aliquots over a period of 2 hours, using 10 min between additions. At all 4 pH values uniformly sized crystals having diameters between 0.5 and 1  $\mu\text{m}$  were obtained.

#### EXAMPLE 8

- 20 Crystallisation of Lys<sup>B29</sup>( $\epsilon$ -myristoyl) des(B30) human insulin in the presence of taurocholic acid sodium salt.

- 10 mg of Lys<sup>B29</sup>( $\epsilon$ -myristoyl) des(B30) human insulin and 5 mg of taurocholic acid sodium salt are dissolved in 500  $\mu\text{l}$  10 mM tris buffer, pH 8.0 in 20 % (v/v) of ethanol in water. To this solution is added 500  $\mu\text{l}$  2 M sodium acetate. Microscopy after 1 hour and after 24 hours shows identically appearance of the crystals, i.e. uniformly sized crystals having diameters between 0.5 and 1  $\mu\text{m}$ . The crystals were washed once with 300  $\mu\text{l}$  10 % (v/v) ethanol in water at -10°C and dried *in vacuo*. HPLC of the crystals showed that the washings had removed the taurocholic acid sodium salt from the crystals of Lys<sup>B29</sup>( $\epsilon$ -

myristoyl) des(B30) human insulin.

## Claims

1. Zinc free insulin crystals having a diameter below 10  $\mu\text{m}$ .
2. Zinc free insulin crystals according to claim 1 having a crystal structure belonging to the cubic crystal system.
- 5 3. Zinc free insulin crystals according to claim 2 in the octadecahedral or dodecahedral crystal forms.
4. Zinc free insulin crystals according to any one of the preceding claims having a diameter in the range of 0.2 to 5  $\mu\text{m}$ , preferably in the range of 0.2 to 2  $\mu\text{m}$ , more preferably in the range of 0.5 and 1  $\mu\text{m}$ .
- 10 5. Zinc free insulin crystals according to any one of the preceding claims wherein the insulin is selected from the group consisting of human insulin, bovine insulin or porcine insulin.
6. Zinc free insulin crystals according to claim 5 wherein the insulin is human insulin.
7. Zinc free insulin crystals according to any one claims 1 to 4, wherein the insulin is a  
15 rapid-acting insulin, preferably des(B30) human insulin, Asp<sup>B28</sup> human insulin or Lys<sup>B28</sup>Pro<sup>B29</sup> human insulin.
8. Zinc free insulin crystals according to any one claims 1 to 4, wherein the insulin is an insulin derivative, preferably selected from the group consisting of B29-N $\epsilon$ -myristoyl-des(B30) human insulin, B29-N $\epsilon$ -palmitoyl-des(B30) human insulin, B29-N $\epsilon$ -myristoyl human insulin, B29-N $\epsilon$ -palmitoyl human insulin, B28-N $\epsilon$ -myristoyl  
20 Lys<sup>B28</sup>Pro<sup>B29</sup> human insulin, B28-N $\epsilon$ -palmitoyl Lys<sup>B28</sup>Pro<sup>B29</sup> human insulin, B30-N $\epsilon$ -myristoyl-Thr<sup>B29</sup>Lys<sup>B30</sup> human insulin, B30-N $\epsilon$ -palmitoyl-Thr<sup>B29</sup>Lys<sup>B30</sup> human insulin, B29-N $\epsilon$ -(N-palmitoyl- $\gamma$ -glutamyl)-des(B30) human insulin, B29-N $\epsilon$ -(N-lithocholyl- $\gamma$ -glutamyl)-des(B30) human insulin, B29-N $\epsilon$ -( $\omega$ -carboxyheptadecanoyl)-des(B30)  
25 human insulin and B29-N $\epsilon$ -( $\omega$ -carboxyheptadecanoyl) human insulin.
9. Zinc free insulin crystals according to claim 8 wherein the insulin is Lys<sup>B29</sup>(N- $\epsilon$ acylated) des(B30) human insulin.
10. Zinc free insulin crystals according to any one of the preceding claims further comprising a stabilizing amount of a phenolic compound.

11. Zinc free insulin crystals according to claim 10 which comprises m-cresol or phenol, or a mixture thereof.
12. A therapeutic powder formulation suitable for pulmonary administration comprising the zinc free crystals according to any one of the preceding claims.
- 5 13. A therapeutic powder formulation according to claim 12 which further comprises an enhancer which enhances the absorption of insulin in the lower respiratory tract.
14. A therapeutic powder formulation according to claim 13 wherein the enhancer is a surfactant.
- 10 15. A therapeutic powder formulation according to claim 14 wherein the surfactant is a salt of a fatty acid, a bile salt or a phospholipid, preferably a bile salt.
16. A therapeutic powder formulation according to claim 15 wherein the surfactant is a salt of taurocholate, preferably sodium taurocholate.
- 15 17. A therapeutic powder formulation according to anyone of claims 12 to 16 which further comprises a carrier, preferably selected from the group consisting of trehalose, raffinose, mannitol, sorbitol, xylitol, inositol, sucrose, sodium chloride and sodium citrate.
18. A method for the preparation of zinc free insulin crystals according to any of the claims 1 to 11, comprising the steps of:
  - 20 a) providing a solution of insulin having a pH between 7.0 and 9.5;
  - b) mixing said solution with a solution of a salt of an alkali metal or an ammonium salt; and
  - c) recovering the formed crystals.
19. A method according to claim 18, wherein the salt of an alkali metal or ammonium is selected from the group consisting of the hydrochloride or acetate of sodium, potassium, lithium or ammonia, or mixtures thereof, preferable sodium acetate.
- 25 20. A method according to claim 18 or 19, wherein the solution of insulin and/or the solution of a salt of an alkali metal or an ammonium salt comprises a water miscible organic solvent in an amount which corresponds to 5 to 25 % (v/v) in the solution obtained after mixing.
- 30 21. A method according to claim 20, wherein the water miscible organic solvent is selected from the group consisting of ethanol, methanol, acetone and 2-propanol,

preferably ethanol.

22. A method according to any one of claims 18 to 21, wherein the two solutions are mixed within a period of less than 2 hours, preferably less than 1 hour, more preferably less than 15 minutes, still more preferably less than 5 minutes.
- 5 23. A method according to any one of claims 18 to 22, wherein the concentration of insulin after mixing is between 0.5% and 10%, preferably between 0.5% and 5%, more preferably between 0.5% and 2%.
24. A method according to any one of claims 18 to 23, wherein the concentration of salt after mixing is between 0.2 M and 2 M, preferably about 1 M.
- 10 25. A method according to any one of claims 18 to 24, which further comprises a washing step, in which the crystals obtained are washed with a solution comprising auxiliary substances to be included in the final dry powder, preferably an enhancer and/or a carbohydrate, and optionally comprising 5-25% of an alcohol, preferably ethanol, 5-50 mM of a preservative preferably phenol, and 0.1-2 M of a salt such as sodium acetate.
- 15 26. Use of zinc free crystals according to any one of the claims 1 to 11 for the manufacture of a therapeutic powder formulation suitable for pulmonary administration in the treatment in diabetes mellitus.
27. A method of treating diabetes mellitus comprising administering to a person in need of such treatment an effective amount of a therapeutic powder formulation according to any one of the claims 12 to 17.
- 20 28. A method of treating diabetes mellitus comprising administering by pulmonary delivery to a person in need of such treatment an effective amount of an insulin derivative having a protracted onset of action, preferably selected from the group consisting of B29-N<sup>ε</sup>-myristoyl-des(B30) human insulin, B29-N<sup>ε</sup>-palmitoyl-des(B30) human insulin, B29-N<sup>ε</sup>-myristoyl human insulin, B29-N<sup>ε</sup>-palmitoyl human insulin, B28-N<sup>ε</sup>-myristoyl Lys<sup>B28</sup> Pro<sup>B29</sup> human insulin, B28-N<sup>ε</sup>-palmitoyl Lys<sup>B28</sup> Pro<sup>B29</sup> human insulin, B30-N<sup>ε</sup>-myristoyl-Thr<sup>B29</sup> Lys<sup>B30</sup> human insulin, B30-N<sup>ε</sup>-palmitoyl-Thr<sup>B29</sup> Lys<sup>B30</sup> human insulin, B29-N<sup>ε</sup>-(N-palmitoyl-γ-glutamyl)-des(B30) human insulin, B29-N<sup>ε</sup>-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin, B29-N<sup>ε</sup>-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N<sup>ε</sup>-(ω-carboxyheptadecanoyl) human insulin.
- 25
- 30





Fig. 1 Photomicrography of the crystals obtained in example 1. The length the bar represents 10  $\mu\text{m}$ .

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00109

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 14/62, A61K 38/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC, PAJ, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3719655 A (R. L. JACKSON), 6 March 1973 (06.03.73)	1-6
Y	--	12-17,25,26
X	EP 0709395 A2 (ELI LILLY AND COMPANY), 1 May 1996 (01.05.96), page 3, line 6 through page 5, line 1	1-8,10-11, 18-19,22-24
Y	--	12-17,25,26
A	--	20-21
Y	US 5506203 A (KJELL G. E. BÄCKSTRÖM ET AL), 9 April 1996 (09.04.96), summary of invention	12-17,25,26
	-----	

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

22 June 1998

Date of mailing of the international search report

02-07-1998

Name and mailing address of the ISA/  
Swedish Patent Office

Authorized officer

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00109

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 27, 28  
because they relate to subject matter not required to be searched by this Authority, namely:  
Methods for treatment of the human body. See PCT Rule 39.1(iv).
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

09/06/98

International application No.

PCT/DK 98/00109

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3719655 A	06/03/73	CA 918565 A	09/01/73
		DE 2018588 A	09/06/71
		DK 127165 B	01/10/73
		FR 2045435 A	26/02/71
		GB 1269185 A	06/04/72
		NL 154423 B	15/09/77
		NL 7005291 A	08/06/71
		SE 371745 B,C	02/12/74
EP 0709395 A2	01/05/96	CA 2161495 A	01/05/96
		JP 8225597 A	03/09/96
		US 5597893 A	28/01/97
US 5506203 A	09/04/96	AU 7090194 A	17/01/95
		AU 7090294 A	17/01/95
		BR 9406907 A	02/04/96
		BR 9406908 A	02/04/96
		CN 1127471 A	24/07/96
		CN 1129904 A	28/08/96
		CZ 9503393 A	15/05/96
		CZ 9503428 A	15/05/96
		EP 0706382 A	17/04/96
		EP 0706383 A	17/04/96
		FI 956227 A	22/12/95
		FI 956228 A	22/12/95
		HU 75065 A	28/03/97
		HU 75066 A	28/03/97
		HU 9503659 D	00/00/00
		HU 9503660 D	00/00/00
		IL 110084 D	00/00/00
		IL 110085 D	00/00/00
		JP 8512027 T	17/12/96
		JP 9500621 T	21/01/97
		LT 1976 A	25/05/95
		LT 1977 A	31/01/95
		LT 3445 B	25/10/95
		LT 3649 B	25/01/96
		MX 9404761 A	31/01/95
		MX 9404762 A	31/01/95
		NO 955226 A	15/02/96
		NO 955227 A	20/02/96
		PL 312205 A	01/04/96
		PL 312210 A	01/04/96
		SK 160195 A	05/02/97
		SK 160295 A	05/03/97
		US 5518998 A	21/05/96
		US 5658878 A	19/08/97
		WO 9500127 A	05/01/95
		WO 9500128 A	05/01/95
		ZA 9404378 A	24/03/95
		ZA 9404379 A	24/03/95
		AU 681661 B	04/09/97
		AU 6694294 A	21/11/94
		SE 9400372 D	00/00/00